Brendon Neuen's Publications

About Brendon Neuen's Publications

Program Lead, Renal and Metabolic
  • Nephrologist and Director, Kidney Trials, Royal North Shore Hospital
  • Clinical Associate Professor, University of Sydney
  • Conjoint Associate Professor, UNSW Sydney
  • Ph.D. ,
  • MBBS(Hons),
  • MSc(Oxon),
  • FRACP,
  • FASN
  • Finerenone in Persons with Chronic Kidney Disease without Diabetes

    New England Journal of Medicine Date published:
  • A Dose of Perspective: A Multinational Survey of Patient and Clinician Views on Combination Therapy in CKD

    Kidney360 Date published:
  • Iron deficiency and risk of heart failure and cardiovascular events in CKD: Insights from the ASCEND-ND trial

    European Journal of Heart Failure Date published:
  • Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals

    Nature Medicine Date published:
  • Efficacy and Safety of Simultaneous Initiation of SGLT2 Inhibitors and Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease or Heart Failure

    JACC: Heart Failure Date published:
  • Kidney Failure Risk Equation and Risk of Kidney and Cardiovascular Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Insights from PARADIGM-HF

    European Journal of Heart Failure Date published:
  • Spironolactone, Early Acute eGFR Changes, and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from TOPCAT Americas

    European Journal of Heart Failure Date published:
  • Is Placebo Still Ethical in Trials of Incretin Therapies?

    Circulation Date published:
  • Lifetime benefits of finerenone on cardiorenal morbidity and mortality in chronic kidney disease and type 2 diabetes: a pooled analysis of FIDELIO-DKD and FIGARO-DKD trials

    European Heart Journal Date published:
  • Effects of anti-inflammatory agents on cardiovascular outcomes: A systematic review and meta-analysis of randomised controlled trials

    American Journal of Preventive Cardiology Date published:
  • Kidney Disease and Heart Failure: Recent Advances and Current Challenges

    JACC: Heart Failure Date published:
  • Effects of Finerenone on Heart Failure Outcomes According to Baseline Heart Failure Risk in Chronic Kidney Disease and Type 2 Diabetes

    JACC: Heart Failure Date published:
  • Kidney disease and heart failure: recent advances and current challenges: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

    Kidney International Date published:
  • SGLT2 inhibition in Patients with Type 2 Diabetes and CKD Experiencing a Deterioration in Estimated Glomerular Filtration Rate to <20ml/min/1.73m2

    Journal of Cardiac Failure Date published:
  • The Association between Low-Grade Proteinuria and Adverse Kidney Outcomes in IgA Nephropathy: A Systematic Review and Meta-Analysis

    Clinical Journal of the American Society of Nephrology Date published:
  • Cardiac Impact of Dapagliflozin in Advanced Chronic Kidney Disease: Rationale and Design of the Renal Lifecycle Trial Cardiac Imaging Sub-studies

    Clinical Kidney Journal Date published: